Published Date: 02 Mar 2023
Although further research is needed, these tools may improve clinical management.
Read Full NewsThe thymus is not routinely considered during thoracic radiotherapy planning, but new findings suggest that may need to change.
Adding rusfertide to standard-of-care treatment cut phlebotomy rates by more than half in the phase 3 VERIFY trial.
1.
Alzheimer's Blood Test Gets FDA Clearance
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
Imfinzi + Imjudo, EU approved for patients with advanced lung cancer and non-small cell lung cancer: AstraZeneca
4.
New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy
5.
AI tool identifies women at high risk of interval breast cancer
1.
Personalized Survivorship Navigation in Precision Cancer Care
2.
The Silent Danger of Hematoma: How to Identify and Treat This Potentially Serious Condition
3.
Evolution of Cancer Care Through Developmental Therapeutics
4.
Breakthroughs in Cancer Care: From Rare Diagnoses to Advanced and Early-Stage Treatments
5.
Boosting Checkpoint Immunotherapy in Hodgkin Lymphoma with JAK Inhibition: Advances & Insights
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation